Core Viewpoint - Peijia Medical-B (09996) shares rose nearly 7%, currently up 6.88% at HKD 6.21, with a trading volume of HKD 7.4878 million [1] Group 1: Company Developments - Peijia Medical announced that on December 11, it received approval from the National Medical Products Administration of the People's Republic of China for the registration application of the TaurusTrio Transcatheter Aortic Valve (TAV) system [1] - The TaurusTrio TAV system is developed and manufactured by the company under an exclusive license obtained from JenaValve Technology, Inc. for the Trilogy Transcatheter Heart Valve (THV) system [1] - The Trilogy THV system received CE mark certification in May 2021 and has been used in over 1,000 commercial surgeries in real-world clinical practice as of the announcement date [1] Group 2: Market Implications - The company anticipates that the successful launch of the TaurusTrio TAV system in China will provide a safe and effective treatment option for patients with severe aortic regurgitation (AR), addressing a significant unmet clinical need [1]
沛嘉医疗-B涨近7% TaurusTrio经导管主动脉瓣系统中国正式获批